zorevunersen
Generic: STK-001·Code: STK-001
zorevunersen: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Stoke Therapeutics, Inc. (STOK) | Phase 3 |
Clinical Trials (1)
An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001
FDA Decisions
FDA_MeetingMultidisciplinary meeting held to discuss clinical development and potential expedited regulatory pathways; no immediate changes agreed; FDA requested additional information.(STOK)
Frequently asked questions
Who is developing zorevunersen?
zorevunersen is being developed by Stoke Therapeutics, Inc..
How many clinical trials involve zorevunersen?
BioSniper tracks 1 clinical trial involving zorevunersen.
What is zorevunersen's latest FDA decision?
The most recent tracked FDA decision for zorevunersen is FDA_Meeting for Multidisciplinary meeting held to discuss clinical development and potential expedited regulatory pathways; no immediate changes agreed; FDA requested additional information..
Get deeper analysis on zorevunersen
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis